Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2728-2729

  Bass, Adam ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; COLORECTAL CARCINOMA; GENE MUTATION; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS; LIGANDS; MAP KINASE SIGNALING SYSTEM; MODELS, BIOLOGICAL; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 79960145543     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.1816     Document Type: Article

References (12)

1. Price TJ, Hardingham JE, Lee CK, et al: Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol 29:2675-2682, 2011
2. Dhillon AS, Hagan S, Rath O, et al: MAP kinase signaling pathways in cancer. Oncogene 26:3279-3290, 2007 (Pubitemid 46763021)
3. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295-308, 2007
4. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
6. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
7. Ellis LM: Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33:S1-S7, 2006 (suppl 10)
8. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
9. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 3534)
10. Engelman JA, Chen L, Tan X, et al: Effective use of PI3K and MEK Inhibitors to treat mutant Kras G12D and PIKCA H1047R murine lung cancers. Nat Med 14:1351-1356, 2008
11. Scholl C, Fröhling S, Dunn IF, et al: Synthetic lethal interactions between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137:821-834, 2009
12. Barbie DA, Tamayo O, Boehm JS, et al: Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462:108-112, 2009